127 related articles for article (PubMed ID: 12135145)
1. Effective disopyramide treatment in a boy with mid-ventricular hypertrophic obstructive cardiomyopathy.
Teraguchi M; Ikemoto Y; Kobayashi Y
Circ J; 2002 Jul; 66(7):709-11. PubMed ID: 12135145
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
Kajimoto K; Harada T; Imamura K; Matsuda N; Niki K; Hagiwara N; Kasanuki H
J Cardiol; 2000 Mar; 35(3):197-203. PubMed ID: 10808427
[TBL] [Abstract][Full Text] [Related]
3. Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report.
Tokudome T; Mizushige K; Ueda T; Sakamoto S; Matsuo H
Angiology; 1999 Apr; 50(4):331-5. PubMed ID: 10225470
[TBL] [Abstract][Full Text] [Related]
4. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
Haruki S; Minami Y; Suzuki A; Hagiwara N
Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
[TBL] [Abstract][Full Text] [Related]
5. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
Verlinden NJ; Coons JC
Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
[TBL] [Abstract][Full Text] [Related]
6. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
[TBL] [Abstract][Full Text] [Related]
7. Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting.
Sirak TE; Sherrid MV
Chest; 2008 May; 133(5):1243-6. PubMed ID: 18460523
[TBL] [Abstract][Full Text] [Related]
8. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
Kajimoto K; Imai T; Minami Y; Kasanuki H
Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
[TBL] [Abstract][Full Text] [Related]
9. Disopyramide use in infants and children with hypertrophic cardiomyopathy.
O'Connor MJ; Miller K; Shaddy RE; Lin KY; Hanna BD; Ravishankar C; Rossano JW
Cardiol Young; 2018 Apr; 28(4):530-535. PubMed ID: 29513203
[TBL] [Abstract][Full Text] [Related]
10. An equation to predict the changes in peak left ventricular pressure in hypertrophic obstructive cardiomyopathy after treatment: application to the administration of disopyramide.
Niki K; Sugawara M; Tanino S; Iwade K; Hosoda S; Kasanuki H
Heart Vessels; 1999; 14(2):72-81. PubMed ID: 10651183
[TBL] [Abstract][Full Text] [Related]
11. Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.
Adler A; Fourey D; Weissler-Snir A; Hindieh W; Chan RH; Gollob MH; Rakowski H
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28550094
[TBL] [Abstract][Full Text] [Related]
12. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
[TBL] [Abstract][Full Text] [Related]
13. [Drug treatment for hypertrophic cardiomyopathy].
Gibelin P
Presse Med; 2009 Jun; 38(6):1001-4. PubMed ID: 19446431
[TBL] [Abstract][Full Text] [Related]
14. Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration.
Pollick C
Am J Cardiol; 1988 Dec; 62(17):1252-5. PubMed ID: 3057852
[TBL] [Abstract][Full Text] [Related]
15. Negative ionotropic agents for the treatment of left ventricular outflow tract obstruction due to sigmoid septum and concentric left ventricular hypertrophy.
Ranasinghe I; Yeoh T; Yiannikas J
Heart Lung Circ; 2011 Sep; 20(9):579-86. PubMed ID: 21684204
[TBL] [Abstract][Full Text] [Related]
16. Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy.
Pernat A; Pohar B; Horvat M
J Electrocardiol; 1997 Oct; 30(4):341-4. PubMed ID: 9375912
[TBL] [Abstract][Full Text] [Related]
17. Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy.
Hongo M; Nakatsuka T; Takenaka H; Tanaka M; Watanabe N; Yazaki Y; Sekiguchi M
Cardiology; 1996; 87(1):6-11. PubMed ID: 8631046
[TBL] [Abstract][Full Text] [Related]
18. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children.
Duncan WJ; Tyrrell MJ; Bharadwaj BB
Can J Cardiol; 1991 Mar; 7(2):81-6. PubMed ID: 2049687
[TBL] [Abstract][Full Text] [Related]
19. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.
Sherrid MV; Arabadjian M
Prog Cardiovasc Dis; 2012; 54(6):483-92. PubMed ID: 22687589
[TBL] [Abstract][Full Text] [Related]
20. Danger of use of disopyramide in patients with hypertrophic obstructive cardiomyopathy. An electrophysiologic study.
Miyajima S; Aizawa Y; Matsuoka A; Okabe M; Shibata A
Jpn Heart J; 1988 Jan; 29(1):115-9. PubMed ID: 3398239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
